Clinical improvement in canine pulmonary hypertension with Perna canaliculus oil (PCSO-524) add-on therapy: Effects on exercise tolerance and cough
Issued Date
2025-09-01
Resource Type
eISSN
19326203
Scopus ID
2-s2.0-105017244016
Journal Title
Plos One
Volume
20
Issue
9 September
Rights Holder(s)
SCOPUS
Bibliographic Citation
Plos One Vol.20 No.9 September (2025)
Suggested Citation
Riengvirodkij N., Taechikantaphat M., Ampapol P., Kovorakul T., Intaranat S., Costa N., Sakcamduang W. Clinical improvement in canine pulmonary hypertension with Perna canaliculus oil (PCSO-524) add-on therapy: Effects on exercise tolerance and cough. Plos One Vol.20 No.9 September (2025). doi:10.1371/journal.pone.0333526 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/112425
Title
Clinical improvement in canine pulmonary hypertension with Perna canaliculus oil (PCSO-524) add-on therapy: Effects on exercise tolerance and cough
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Pulmonary hypertension (PH) in dogs, characterized by abnormally high blood pressure in the pulmonary arteries, presents a management challenge, and adjunctive therapies for the standard treatment of sildenafil are needed. This study aimed to determine whether the nutraceutical Perna canaliculus oil (PCSO-524), a marine lipid extract with anti-inflammatory properties, provides additional clinical benefits to dogs with PH. In a prospective, randomized, placebo-controlled trial, seventeen client-owned dogs diagnosed with PH were assigned to receive either PCSO-524 or a placebo as an add-on to their sildenafil-based therapy for 70 days. Key outcomes were evaluated using owner-assessed clinical scores for exercise tolerance and coughing, alongside echocardiographic measurements. The PCSO-524 group demonstrated a statistically significant improvement in exercise tolerance scores by day 70 (P = 0.009). This group also showed a greater reduction in coughing scores compared to the placebo group between day 35 and day 70 (P = 0.03). While the tricuspid regurgitation pressure gradient (TRPG), an estimate of pulmonary pressure, decreased significantly over time in all dogs (P = 0.001), no significant difference was found between the groups for this specific measure. These results indicate that PCSO-524 can serve as a beneficial adjunctive therapy for improving important clinical signs, such as exercise tolerance and coughing, in dogs with PH. This suggests it may be a valuable addition to standard management for enhancing quality of life.